Rituximab and tafasitamab with donor immune cells for lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of B-cell non-Hodgkin lymphoma (like DLBCL, follicular lymphoma, or others) that has returned or not responded to at least two prior treatments.
- You must have a measurable sign of disease (like a tumor at least 1.5 cm on a CT scan) or, for CLL, certain blood cell changes or enlarged lymph nodes.
- You must have tried therapies that target CD19 or CD20 before, and a recent biopsy must show your cancer cells still have these targets.
- You must be in fairly good health with adequate organ function (liver, kidneys, heart, and lungs) and able to perform daily activities (ECOG 0-2).
- You cannot have other active cancers, serious heart conditions, uncontrolled HIV or hepatitis, active autoimmune disease needing strong immune suppressive drugs, or untreated lymphoma in the brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (tafasitamab, lenalidomide, and rituximab) for people with newly diagnosed follicular or marginal zone lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
This study tests a new way to treat slow-growing non-Hodgkin lymphoma that has come back or not responded to other treatments. It combines special immune cells with a targeted therapy to try to destroy cancer cells.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.